Top-Rated Stocks NASDAQ:SRPT Sarepta Therapeutics - SRPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $137.83 +1.80 (+1.32%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$136.73▼$139.1850-Day Range$117.84▼$155.9952-Week Range$61.28▼$159.84Volume1.23 million shsAverage Volume1.42 million shsMarket Capitalization$12.13 billionP/E RatioN/ADividend YieldN/APrice Target$166.41 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside20.7% Upside$166.41 Price TargetShort InterestHealthy6.18% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment1.05Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.44) to $7.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector178th out of 1,004 stocksPharmaceutical Preparations Industry76th out of 489 stocks 3.5 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $166.41, Sarepta Therapeutics has a forecasted upside of 20.7% from its current price of $137.83.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.18% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 32.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 3.9 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Sarepta Therapeutics this week, compared to 4 articles on an average week.Search Interest45 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 1,025% compared to the previous 30 days.MarketBeat Follows16 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions87.31% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($5.44) to $7.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 31.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics (NASDAQ:SRPT) StockSarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.Read More Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesMarch 21, 2023 | marketbeat.comWhy did Sarepta Therapeutics Stock Plummet?SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.March 31, 2023 | benzinga.comROSEN, National Trial Lawyers, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 31, 2023 | marketwatch.comROSEN, A LEADING AND RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTMarch 30, 2023 | finance.yahoo.comSarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?March 29, 2023 | finance.yahoo.comSarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock advances 3.7% this past weekMarch 29, 2023 | businesswire.comSAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the FirmMarch 26, 2023 | americanbankingnews.comBrokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $166.41April 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 25, 2023 | finance.yahoo.com3 Up-and-Coming Growth Stocks to Buy Right NowMarch 23, 2023 | americanbankingnews.comTD Cowen Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $175.00March 22, 2023 | markets.businessinsider.comTD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To KnowMarch 22, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Sarepta TherapeuticsMarch 21, 2023 | finance.yahoo.comSarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?March 21, 2023 | americanbankingnews.comCantor Fitzgerald Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $165.00March 21, 2023 | americanbankingnews.comMizuho Reaffirms "Buy" Rating for Sarepta Therapeutics (NASDAQ:SRPT)March 21, 2023 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given New $160.00 Price Target at Needham & Company LLCMarch 20, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)March 17, 2023 | finance.yahoo.comSarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001March 17, 2023 | finance.yahoo.comSarepta Crashes On An Unexpected Roadblock For Its Gene TherapyMarch 17, 2023 | benzinga.comSarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: AnalystMarch 17, 2023 | seekingalpha.comHot Stocks: XPEV rises on earnings; MARA, MSTR, RIOT boosted by crypto rise; FRC, SRPT slideMarch 17, 2023 | benzinga.comSarepta Therapeutics Unusual Options Activity For March 17March 17, 2023 | finance.yahoo.comWhy Weakness in Sarepta Therapeutics Is Likely to ContinueMarch 17, 2023 | finance.yahoo.comSarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene TherapyMarch 17, 2023 | investorplace.comWhy Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?March 17, 2023 | reuters.comSarepta slides as surprise FDA panel meeting adds uncertainty for gene therapySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Company Calendar Last Earnings2/28/2023Today3/31/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,162Year Founded1980Price Target and Rating Average Stock Price Forecast$166.41 High Stock Price Forecast$206.00 Low Stock Price Forecast$122.00 Forecasted Upside/Downside+20.7%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($8.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-703,490,000.00 Net Margins-75.40% Pretax Margin-73.95% Return on Equity-117.29% Return on Assets-22.81% Debt Debt-to-Equity Ratio4.01 Current Ratio4.13 Quick Ratio3.80 Sales & Book Value Annual Sales$933.01 million Price / Sales13.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.39 per share Price / Book31.40Miscellaneous Outstanding Shares87,980,000Free Float82,351,000Market Cap$12.13 billion OptionableOptionable Beta0.97 Social Links Key ExecutivesDouglas S. IngramPresident, Chief Executive Officer & DirectorIan M. EstepanExecutive VP, Chief Financial & Accounting OfficerLouise Rodino-KlapacChief Scientific Officer & Executive VPBilal ArifChief Technical Operations Officer & Executive VPDiane BerryEVP, Chief Global Policy & Advocacy OfficerKey CompetitorsCatalentNYSE:CTLTViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRTeva Pharmaceutical IndustriesNYSE:TEVADr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 2,568 shares on 3/27/2023Ownership: 0.003%MetLife Investment Management LLCSold 133 shares on 3/23/2023Ownership: 0.006%ETF Managers Group LLCBought 4,569 shares on 3/23/2023Ownership: 0.005%Victory Capital Management Inc.Sold 139,177 shares on 3/10/2023Ownership: 0.065%Voya Investment Management LLCBought 11,547 shares on 2/28/2023Ownership: 0.067%View All Insider TransactionsView All Institutional Transactions SRPT Stock - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price forecast for 2023? 14 brokers have issued 12-month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $206.00. On average, they expect the company's stock price to reach $166.41 in the next year. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2023? Sarepta Therapeutics' stock was trading at $129.58 at the start of the year. Since then, SRPT shares have increased by 6.4% and is now trading at $137.83. View the best growth stocks for 2023 here. Are investors shorting Sarepta Therapeutics? Sarepta Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 5,440,000 shares, a drop of 32.7% from the February 28th total of 8,080,000 shares. Based on an average trading volume of 1,360,000 shares, the short-interest ratio is presently 4.0 days. View Sarepta Therapeutics' Short Interest. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Tuesday, February, 28th. The biotechnology company reported ($1.24) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.04. The biotechnology company had revenue of $258.43 million for the quarter, compared to analyst estimates of $250.51 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 117.29% and a negative net margin of 75.40%. Sarepta Therapeutics's revenue for the quarter was up 28.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.42) EPS. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), American Century Mid Cap Growth Impact (MID), Invesco Dynamic Biotechnology & Genome ETF (PBE) and AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sands Capital Management LLC (2.45%), Geode Capital Management LLC (1.39%), Avidity Partners Management LP (1.20%), Norges Bank (0.98%), Price T Rowe Associates Inc. MD (0.95%) and Assenagon Asset Management S.A. (0.83%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $137.83. How much money does Sarepta Therapeutics make? Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $12.13 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($8.03) on an earnings per share basis. How many employees does Sarepta Therapeutics have? The company employs 1,162 workers across the globe. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038. This page (NASDAQ:SRPT) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.